ALS

At the Southeastern Neurodegenerative Disease Conference, main focus was advancing careers of newest investigators.

Drs. James Wymer and Michael Okun contributed to annual NEJM Group publication.

UF neuroscientists collaborate on international study revealing a potential therapeutic target for ALS, FTD linked to TDP-43.

AMX0035 was tested at UF, Mass General and partnering sites and then approved by the FDA to treat ALS.

Ariel Walker is the latest MBI Rising Star, a video series highlighting up-and-coming neuroscience researchers at UF.

Trial drug combination shows potential to prolong survival of ALS patients by more than six months.

UF was the No. 2 enroller of patients for multisite ALS trial.

Research led by Drs. Laura Ranum and Tao Zu is encouraging for future treatments for a type of ALS and several other neurological diseases.

One family raised the bar for excellence at UF’s movement disorders program. Learn more in the latest edition of Florida Physician.

Novel type of immunotherapy used in mouse-model study shows promise for ALS treatment.